exRNAdisease

Entry Detail

---



General Information

Database ID: exR0089047 RNA Name: hsa-miR-541-3p RNA Type: miRNA Chromosome: chr14 Starnd: + Coordinate: Start Site(bp): 101064548 End Site(bp): 101064569 External Links: hsa-miR-541-3p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand REPIN1 chr7 150368189 150374044 + HOXD11 chr2 176104216 176109754 + LY6E chr8 143017982 143023832 + FASN chr17 82078338 82098294 - M6PR chr12 8940361 8949761 - TOM1L2 chr17 17843511 17972422 - ACACA chr17 37084992 37406836 - TAF4 chr20 61953469 62065810 - MID1IP1 chrX 38801432 38806537 + FBXO46 chr19 45710629 45730896 - BICRA chr19 47608196 47703277 + CALR chr19 12938578 12944489 + ARHGDIA chr17 81867721 81871378 - UCP2 chr11 73974672 73983246 - FKBP1A chr20 1368978 1393172 - SLC6A6 chr3 14402576 14489349 + NFIX chr19 12995608 13098796 + ADGRL1 chr19 14147743 14206187 - NID1 chr1 235975830 236065109 - CAPZB chr1 19338775 19485539 - AGRN chr1 1020120 1056118 + AXL chr19 41219223 41261766 + MAFG chr17 81918270 81927735 - PKM chr15 72199029 72231822 - IGFBP5 chr2 216672105 216695549 - MIGA2 chr9 129036621 129072082 + ZMIZ1 chr10 79068966 79316528 + PRRC2B chr9 131373636 131500197 + ACVR1B chr12 51951699 51997078 + DMWD chr19 45782947 45792845 - miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0000417 chr12 69644908 69656342 + hsa_circ_0000642 chr15 80390757 80415142 + hsa_circ_0000816 chr17 80521229 80526077 + hsa_circ_0000643 chr15 80412669 80415142 + hsa_circ_0000943 chr19 47421744 47440665 + lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC239868.1 chr1 149861271 149862504 + AL035458.2 chr20 34234840 34281173 - AL356488.2 chr1 109100193 109100619 + NEAT1 chr11 65422774 65445540 + NORAD chr20 36045618 36051018 - OIP5-AS1 chr15 41283990 41309737 + STAG3L5P-PVRIG2P-PILRB chr7 100336104 100367831 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.